Lucknow Speciality Pharma

Eculizumab Injection 300 mg
Eculizumab Injection, this medication is used to treat a certain blood disorder (paroxysmal nocturnal hemoglobinuria). This disorder can cause a decrease in red blood cells (anemia).Patient Support Number +91-9555306364, 9 am - 8 pm IST or send us a request on email (urgent@lucknowpharma.com) /WhatsApp for the same.
Get The Best Access Price
WhatsApp

Eculizumab injection,  U.S. Food and Drug Administration today approved Soliris (eculizumab) injection for intravenous use for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive in 2017.

Eculizumab Injection Available Price In Lucknow Banaras Nepal

Eculizumab Injection

  • Generic Brand Available – Soliris
  • API – Eculizumab
  • Packaging – Glass BOttle
  • Strength – 300 mg

What is Eculizumab Injection used for?

 Eculizumab injection is used to treat a type of blood disease called paroxysmal nocturnal hemoglobinuria (PNH). This medicine helps reduce red blood cell destruction or breakdown (hemolysis) in patients with PNH

    Get Access To Eculizumab Injection 300 mg

    Lucknow Speciality Pharma is a registered Pharmaceutica Firm in Lucknow, India. Registered under GST Act. Registration Number : 09AAOPG3102HIZY. It provide assistance and connectivity with drug pharmacies or distributors for access to genuine medicines at competitive prices. We help through our network for prescription innovator medicine, brand, and generic pharmaceuticals and over-the-counter (OTC) health care products.

    Lucknow Speciality Pharma

    Mobile : 9140551027 / 9794360370
    WhatsApp: +91-9555306364
    E: info@lucknowpharma.com
    Website: www.lucknowpharma.com

    Generic Subsitiute Medicines Available in India

    Breast cancer, Prostate cancer, Skin cancer (melanoma), Colon cancer, Lung cancer, Leukemia, Lymphoma etc

    Generic Subsitiute Medicines Available in India

    Anemia, Diabetes, Hepatitis B & Hepatitis C, HIV,  Asthama, Bone Marrow, Cardiology, Rheumatoid Arthritis, Fungal Disease, Multiple Sclerosis (MS) etc.

    US FDA Approved Imported Medicines Available in India

    Breast cancer, Prostate cancer, Skin cancer (melanoma), Colon cancer, Lung cancer, Leukemia, Lymphoma etc

    Branch Offices in India : Lucknow | Agra | Varanasi | Gorakhpur | Kanpur | Nepal

    Facts of Medicines

    Eculizumab Injection 300 mg

    STORAGE AND HANDLING

    Eculizumab must be refrigerated at 2°C to 8°C (36°F to 46°F). Do not use the Eculizumab beyond the expiration date located on the carton and the vial.

    DOSAGE

    Only administer as an intravenous infusion. Do not administer as an intravenous push or bolus injection. Administer the Soliris admixture by intravenous infusion over 35 minutes in adults and 1 to 4 hours in pediatric patients via gravity feed, a syringe-type pump, or an infusion pump.

    SIDE EFFECTS

    Eculizumab may cause serious side effects including: hives, difficulty breathing, swelling of your face, lips, tongue, or throat, abnormal liver function tests, chest pain, new or a worsening irregular heartbeats pattern, nausea, upper stomach pain, itching, tired feeling, loss of appetite, dark urine, clay-colored stools, and yellowing of the skin or eyes.

    WARNINGS AND PRECAUTIONS

    Genetic testing should be indicated in order to detect whether a person is at higher risk of developing hypersensitivity.

    Eculizumab may not be added as a single agent when antiretroviral regimens are changed because of loss of the virologic response.

    Patients with liver disease should be watchful and cautious in order to Eculizumab because it can aggravate the condition.

    In patients with Eculizumab, conditions like immune reconstitution inflammatory syndrome, a change in body fat as well as an increased risk of heart attack may occur.

    Eculizumab is not recommended for use in infants who are under 3 months of age.

    Sometimes serious hypersensitivity reactions have been associated with Eculizumab.

    FAQs – Medicine Questions

    Eculizumab Injection 300 mg
    What is eculizumab used to treat?
    Eculizumab injection is used to treat a type of blood disease called paroxysmal nocturnal hemoglobinuria (PNH). This medicine helps reduce red blood cell destruction or breakdown (hemolysis) in patients with PNH.
    What is eculizumab infusion?
    SOLIRIS® (eculizumab) is an infusion prescription medication used to treat adults with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody-positive. Adults may also have paroxysmal nocturnal hemoglobinuria (PNH), hemolytic uremic syndrome (aHUS), and myasthenia gravis.
    How is Soliris given?
    Only administer as an intravenous infusion. Do not administer as an intravenous push or bolus injection. Administer the Soliris admixture by intravenous infusion over 35 minutes in adults and 1 to 4 hours in pediatric patients via gravity feed, a syringe-type pump, or an infusion pump.
    Where can I buy Eculizumab Injection?

    You can buy Eculizumab Injection from any authorized whole-seller after getting a prescription from a qualified doctor. It is always better to check the credential of the whole-seller/supplier/exporter before buying the product.

    The buyer should check the existing law in their home country before importing the product.

    What is the procedure to buy Eculizumab Injection?

    Patients can simply fill the order form or can send mail at info@lucknowpharma.com. Patients can also send WhatsApp messages to +91-9555306364 We will reply ASAP with the details of the Eculizumab Injeion price as well as procurement procedure.

    Note:- The order will be confirmed only after the receipt of the Valid prescription of the Clinician.

    Is Soliris a chemo drug?
    Eculizumab is the generic name for the trade chemotherapy drug Soliris. In some cases, health care professionals may use the trade name Soliris when referring to the generic drug name eculizumab. Soliris (eculizumab) may be the most effective and well-tolerated immunotherapy for patients with myasthenia gravis (MG), according to an analysis of multiple studies.

    NEWS / UPDATES